# | Title | Journal | Year | Citations |
---|
1 | Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. | Journal of Clinical Oncology | 1997 | 5,294 |
2 | The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. | Journal of Clinical Oncology | 1993 | 5,004 |
3 | Final Version of 2009 AJCC Melanoma Staging and Classification | Journal of Clinical Oncology | 2009 | 4,126 |
4 | Revised Response Criteria for Malignant Lymphoma | Journal of Clinical Oncology | 2007 | 4,061 |
5 | One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States | Journal of Clinical Oncology | 2008 | 3,875 |
6 | Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes | Journal of Clinical Oncology | 2009 | 3,730 |
7 | Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification | Journal of Clinical Oncology | 2014 | 3,729 |
8 | Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer | Journal of Clinical Oncology | 2000 | 3,563 |
9 | Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group | Journal of Clinical Oncology | 2007 | 3,396 |
10 | Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update | Journal of Clinical Oncology | 2013 | 3,276 |
11 | Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group | Journal of Clinical Oncology | 2010 | 3,222 |
12 | Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas | Journal of Clinical Oncology | 1999 | 3,209 |
13 | Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients | Journal of Clinical Oncology | 2001 | 3,157 |
14 | Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World | Journal of Clinical Oncology | 2006 | 3,155 |
15 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer | Journal of Clinical Oncology | 2007 | 3,139 |
16 | Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States | Journal of Clinical Oncology | 2011 | 3,060 |
17 | Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer | Journal of Clinical Oncology | 2008 | 3,032 |
18 | Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2008 | 3,032 |
19 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations | Journal of Clinical Oncology | 2013 | 2,854 |
20 | Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2003 | 2,822 |
21 | Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma | Journal of Clinical Oncology | 2003 | 2,796 |
22 | Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study | Journal of Clinical Oncology | 2008 | 2,735 |
23 | FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study | Journal of Clinical Oncology | 2004 | 2,718 |
24 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology | 2018 | 2,691 |
25 | Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates | Journal of Clinical Oncology | 2010 | 2,667 |
26 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer | Journal of Clinical Oncology | 2010 | 2,667 |
27 | Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease | Journal of Clinical Oncology | 1999 | 2,628 |
28 | Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis | Journal of Clinical Oncology | 2005 | 2,625 |
29 | Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. | Journal of Clinical Oncology | 1998 | 2,616 |
30 | Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer | Journal of Clinical Oncology | 2002 | 2,612 |
31 | Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma | Journal of Clinical Oncology | 2001 | 2,462 |
32 | Interpreting the significance of changes in health-related quality-of-life scores. | Journal of Clinical Oncology | 1998 | 2,443 |
33 | Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Journal of Clinical Oncology | 2003 | 2,425 |
34 | International Staging System for Multiple Myeloma | Journal of Clinical Oncology | 2005 | 2,404 |
35 | Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System | Journal of Clinical Oncology | 2001 | 2,394 |
36 | Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer | Journal of Clinical Oncology | 2008 | 2,387 |
37 | Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer | Journal of Clinical Oncology | 2006 | 2,369 |
38 | Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy | Journal of Clinical Oncology | 2004 | 2,330 |
39 | Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Journal of Clinical Oncology | 2010 | 2,287 |
40 | How To Build and Interpret a Nomogram for Cancer Prognosis | Journal of Clinical Oncology | 2008 | 2,273 |
41 | Response criteria for phase II studies of supratentorial malignant glioma. | Journal of Clinical Oncology | 1990 | 2,260 |
42 | Immune Checkpoint Blockade in Cancer Therapy | Journal of Clinical Oncology | 2015 | 2,220 |
43 | Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma | Journal of Clinical Oncology | 2009 | 2,219 |
44 | Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor | Journal of Clinical Oncology | 2003 | 2,160 |
45 | Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Journal of Clinical Oncology | 2007 | 2,159 |
46 | Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group | Journal of Clinical Oncology | 2009 | 2,151 |
47 | Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group | Journal of Clinical Oncology | 2008 | 2,119 |
48 | A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer | Journal of Clinical Oncology | 2004 | 2,112 |
49 | Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy | Journal of Clinical Oncology | 2000 | 2,074 |
50 | Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes | Journal of Clinical Oncology | 2012 | 2,062 |